indication

Schizophrenia Spectrum and Other Psychotic Disorders

Competitive landscape projected to Stakeholder feedback’s launch window

as of 2026-07-01
Competitive set
16
8 approved · 8 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
52 events
2020
2024
2028
2032
2036
2040
today
Stakeholder feedback launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 43 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Haloperidol
US-approved 1986 · Haldol Decanoate
Phase 42 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugCompleted
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 42 trials
OwnerJohnson & Johnson
Protection2041
drugCompleted
Aripiprazole
US-approved 2002 · ABILIFY
—2 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugCompleted
Ziprasidone
US-approved 2001 · Geodon
Phase 42 trials
OwnerPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Protection—
drugCompleted
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 41 trial
OwnerEli Lilly and Company
Protection2041
drugCompleted
Quetiapine
US-approved 1997 · SEROQUEL XR
Phase 41 trial
OwnerAstraZeneca
Protection—
drugUnknown
Asenapine
US-approved 2009 · SAPHRIS
Phase 41 trial
OwnerOrganon and Co
Protection2033
drugCompleted
Emraclidine
Pipeline · Phase 2
Phase 24 trials
OwnerCerevel Therapeutics, LLC
Protection—
drugCompleted
Minocycline
Pipeline · Phase 2
Phase 21 trial
OwnerShalvata Mental Health Center
Protection—
drugCompleted
Amisulpride
Pipeline · Phase 4
Phase 41 trial
OwnerSanofi
Protection2038
drugCompleted
Perphenazine
Pipeline · Phase 4
Phase 41 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection—
drugCompleted
Sulpiride
Pipeline · Phase 4
Phase 41 trial
OwnerHannover Medical School
Protection—
drugCompleted
Zuclopenthixol
Pipeline · Phase 4
Phase 41 trial
OwnerBirte Glenthoj
Protection—
drugCompleted
Fluphenazine
Pipeline · Phase 4
Phase 41 trial
OwnerHannover Medical School
Protection—
drugCompleted
Flupentixol
Pipeline · Phase 4
Phase 41 trial
OwnerTechnical University of Munich
Protection—

Market size

prevalence as a range, not a number